Patisiran - Alnylam Pharmaceuticals
Alternative Names: ALN-18328; ALN-TTR02; GENZ-438027; ONPATTRO; Onpattro; Patisiran sodium - Alnylam Pharmaceuticals; patisiran-LNP; SAR-438037Latest Information Update: 06 May 2024
At a glance
- Originator Alnylam Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action Prealbumin expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Amyloid polyneuropathy; Amyloidosis
Most Recent Events
- 30 Apr 2024 Alnylam Pharmaceuticals expands its agreement with Medison Pharma to commercialise Patisiran, in additional Latin America and APAC markets including Australia
- 09 Oct 2023 Alnylam Therapeutics receives complete response letter from the US FDA for patisiran for Cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis
- 13 Sep 2023 Alnylam Pharmaceuticals announces positive outcome of the US FDA CRDAC meeting for sNDA for patisiran